Compare Ascendis Pharma A/S (ASND) vs Dominion Energy Inc (D) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Dominion Energy Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Dominion Energy Inc trades at $69.98 (market cap $61.64B). The key difference: Dominion Energy Inc is far larger — about 3.5× Ascendis Pharma A/S's market cap, and Dominion Energy Inc pays a 3.81% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | D | |
|---|---|---|
Market Cap | $17.74B | $61.64B |
Sector | Health | Utilities |
52-Week High | $277.18 | $70.08 |
52-Week Low | $163.32 | $56.55 |
Enterprise Value | $18.11B | $114.04B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Dominion Energy (D) trades at $70.08, up 0.91% today, near its consensus price target of $69.50. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $16.51B in 2025 with net income margin expanding to 18.16%. The pending $66.8B acquisition by NextEra Energy dominates news flow, positioning Dominion as key infrastructure for AI data center power demand.
Investment outlook balances acquisition premium potential against regulatory approval risks. Strong profitability trends and strategic positioning in power infrastructure support upside, but deal uncertainty and high debt levels pose near-term volatility. Wall Street sentiment is cautious with 59% hold ratings, reflecting wait-and-see approach pending merger resolution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Dominion Energy Inc
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →
